Patients with glioblastoma—the deadliest type of primary brain tumor—may potentially benefit from immunotherapy medications called immune checkpoint inhibitors that stimulate an immune response ...
Patients with glioblastoma - the deadliest type of primary brain tumor - may potentially benefit from immunotherapy medications called immune checkpoint inhibitors that stimulate an immune response ...
Immune checkpoint inhibitors that have revolutionized the treatment of multiple cancers, have failed in all randomized clinical trials in glioblastoma patients. One reason for this failure is that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results